Katzen B T, Edwards K C, Albert A S, van Breda A
J Vasc Surg. 1984 Sep;1(5):718-22. doi: 10.1067/mva.1984.avs0010718.
One hundred thirty patients underwent low-dose, catheter-directed fibrinolytic therapy for arterial and graft occlusions present for various periods of time. In 65 consecutive patients the therapeutic parameters were identical, and a careful hematologic evaluation was performed. In the subsequent 65 patients, varying doses of fibrinolytic agents were employed. Fibrinolytic therapy was found to be beneficial in a diverse group of clinical situations and in patients whose occlusions had occurred at varying lengths of time. Early study demonstrated that effective fibrinolysis can be achieved at approximately one-twentieth of the systemic level and that systemic effects could be avoided in all patients during 24-hour infusions and in many patients infused up to 96 hours. Bleeding complications occurred only in patients in whom concomitant heparinization was employed, and this was thought to be the causative factor. Therapeutic success and avoiding complications are strongly dependent on close monitoring of patients and joint decision making by the vascular surgeon and radiologist.
130例患者因不同时期出现的动脉和移植物闭塞接受了低剂量导管定向纤维蛋白溶解治疗。在连续65例患者中,治疗参数相同,并进行了仔细的血液学评估。在随后的65例患者中,使用了不同剂量的纤维蛋白溶解剂。发现纤维蛋白溶解疗法在多种临床情况下以及在闭塞发生时间不同的患者中都是有益的。早期研究表明,在大约为全身水平二十分之一的剂量下即可实现有效的纤维蛋白溶解,并且在24小时输注期间所有患者以及在长达96小时输注的许多患者中都可避免全身效应。出血并发症仅发生在同时使用肝素化的患者中,这被认为是致病因素。治疗成功和避免并发症在很大程度上取决于对患者的密切监测以及血管外科医生和放射科医生的共同决策。